Cure TV

The science behind immunotherapy and gastrointestinal cancers is not quite perfected yet, but one subset of patients is seeing remarkable results.

The Leukemia & Lymphoma Society's (LLS) Clinical Trial Support Center helps patients with blood cancers find clinical trials that are right for them.

After finding out she had an MPN, Barbara Abernathy, Ph.D., like many other people, felt numb. But then it was time to find her fight mode.

Patients with non-muscle invasive bladder cancer experience high levels of distress, according to one study.

While there is no test, such as a mamogram or colonoscopy, for uterine cancer, vaginal bleeding is a telltale sign of the disease.

Many patients with ovarian cancer have misconceptions about the care they will receive while on a clinical trial, according to Laurel W. Rice, M.D.

While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.

Yoga and Reiki can have great benefits for patients undergoing cancer treatment, according to Patrick Dempsey.

Patients with PV tend to be very symptomatic, but Jakafi can help.

When asked about her favorite thing about Thea's Star of Hope, the ten-year-old explained that the organization is like a laser on pediatric brain tumors, shooting at them until, hopefully one day, poof! They disappear.

The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.

William J. Gradishar, M.D., discusses the potential surgical implications for a woman with breast cancer who tests positive for a BRCA mutation, and why it is important to be aware of this genetic information.

The time has finally come when researchers have found a way to harness the immune system and use it to fight blood cancers.

Immunotherapy use continues to expand in the cancer treatment space. So, it is important that patients and caregivers understand its potential side effects.

The definition of smoldering myeloma was reworked in recent years.

Colorectal cancer expert John Marshall, M.D., shares his feelings about the month of March, which is Colorectal Cancer Awareness month.

Ruben Mesa, M.D., director of the UT Health San Antonio Cancer Center, discusses complementary therapy for patients with myeloproliferative neoplasms (MPNs).

Joshua Bauml, M.D., assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the potential of therapeutic vaccine in patients who have head and neck cancer.

William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

Now that we're in an era of personalized medicine, patients should not look at statistics and immediately think that they will determine their fate, says Tom Stockwell, patient navigator at the Fibrolamellar Cancer Foundation.

Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.

Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Carole Brennan Miller, M.D., head of the Cancer Institute at Saint Agnes Hospital, explains what makes people with myeloproliferative neoplasms (MPNs) unique, and why she finds it interesting to work with them.

A myeloproliferative neoplasm survivor and advocate offers advice on how loved ones can support a patient with cancer.

Cristiana Sessa, M.D., of the Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.

Susan Leclair, Ph.D., CLS (NCA), retired lab professor at University of Massachusetts, Dartmouth, discusses how moderating an online forum for patients with myeloproliferative neoplasms (MPNs) has inspired her.

Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, addresses a common myth about clinical trials.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.